Literature DB >> 24393743

Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways.

Fabienne Guillaumond1, Juan Lucio Iovanna1, Sophie Vasseur2.   

Abstract

Because of lack of effective treatment, pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of death by cancer in Western countries, with a very weak improvement of survival rate over the last 40years. Defeat of numerous conventional therapies to cure this cancer makes urgent to develop new tools usable by clinicians for a better management of the disease. Aggressiveness of pancreatic cancer relies on its own hallmarks: a low vascular network as well as a prominent stromal compartment (desmoplasia), which creates a severe hypoxic environment impeding correct oxygen and nutrients diffusion to the tumoral cells. To survive and proliferate in those conditions, pancreatic cancer cells set up specific metabolic pathways to meet their tremendous energetic and biomass demands. However, as PDAC is a heterogenous tumor, a complex reprogramming of metabolic processes is engaged by cancer cells according to their level of oxygenation and nutrients supply. In this review, we focus on the glycolytic activity of PDAC and the glucose-connected metabolic pathways which contribute to the progression and dissemination of this disease. We also discuss possible therapeutic strategies targeting these pathways in order to cure this disease which still until now is resistant to numerous conventional treatments.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glutaminolysis; Glycolysis; Hexosamine; Hypoxia; Metabolism; Pancreatic cancer

Mesh:

Substances:

Year:  2014        PMID: 24393743     DOI: 10.1016/j.abb.2013.12.019

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  28 in total

1.  Circulating Metabolites and Survival Among Patients With Pancreatic Cancer.

Authors:  Chen Yuan; Clary B Clish; Chen Wu; Jared R Mayers; Peter Kraft; Mary K Townsend; Mingfeng Zhang; Shelley S Tworoger; Ying Bao; Zhi Rong Qian; Douglas A Rubinson; Kimmie Ng; Edward L Giovannucci; Shuji Ogino; Meir J Stampfer; John Michael Gaziano; Jing Ma; Howard D Sesso; Garnet L Anderson; Barbara B Cochrane; JoAnn E Manson; Margaret E Torrence; Alec C Kimmelman; Laufey T Amundadottir; Matthew G Vander Heiden; Charles S Fuchs; Brian M Wolpin
Journal:  J Natl Cancer Inst       Date:  2016-01-11       Impact factor: 13.506

2.  The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer.

Authors:  Hisataka Ogawa; Hiroaki Nagano; Masamitsu Konno; Hidetoshi Eguchi; Jun Koseki; Koichi Kawamoto; Naohiro Nishida; Hugh Colvin; Akira Tomokuni; Yoshito Tomimaru; Naoki Hama; Hiroshi Wada; Shigeru Marubashi; Shogo Kobayashi; Masaki Mori; Yuichiro Doki; Hideshi Ishii
Journal:  Mol Clin Oncol       Date:  2015-01-22

3.  Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.

Authors:  Fabienne Guillaumond; Ghislain Bidaut; Mehdi Ouaissi; Stéphane Servais; Victoire Gouirand; Orianne Olivares; Sophie Lac; Laurence Borge; Julie Roques; Odile Gayet; Michelle Pinault; Cyrille Guimaraes; Jérémy Nigri; Céline Loncle; Marie-Noëlle Lavaut; Stéphane Garcia; Anne Tailleux; Bart Staels; Ezequiel Calvo; Richard Tomasini; Juan Lucio Iovanna; Sophie Vasseur
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

4.  Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer.

Authors:  Julius Chapiro; Surojit Sur; Lynn Jeanette Savic; Shanmugasundaram Ganapathy-Kanniappan; Juvenal Reyes; Rafael Duran; Sivarajan Chettiar Thiruganasambandam; Cassandra Rae Moats; MingDe Lin; Weibo Luo; Phuoc T Tran; Joseph M Herman; Gregg L Semenza; Andrew J Ewald; Bert Vogelstein; Jean-François Geschwind
Journal:  Clin Cancer Res       Date:  2014-10-17       Impact factor: 12.531

5.  A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.

Authors:  Jianliang Zhang; Di-Hua He; Maria Zajac-Kaye; Steven N Hochwald
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Thalidomide inhibits proliferation and epithelial-mesenchymal transition by modulating CD133 expression in pancreatic cancer cells.

Authors:  Congying Chen; Ge Yu; Wenqin Xiao; Miao Xing; Jianbo Ni; Rong Wan; Guoyong Hu
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

7.  Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production.

Authors:  Yingchao Fan; Yu Gan; Yuling Shen; Xiaojin Cai; Yanfang Song; Fangyu Zhao; Ming Yao; Jianren Gu; Hong Tu
Journal:  Oncotarget       Date:  2015-06-30

8.  Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.

Authors:  Martina D'Aronzo; Manlio Vinciguerra; Tommaso Mazza; Concetta Panebianco; Chiara Saracino; Stephen P Pereira; Paolo Graziano; Valerio Pazienza
Journal:  Oncotarget       Date:  2015-07-30

9.  Enriched environment inhibits mouse pancreatic cancer growth and down-regulates the expression of mitochondria-related genes in cancer cells.

Authors:  Guohua Li; Yu Gan; Yingchao Fan; Yufeng Wu; Hechun Lin; Yanfang Song; Xiaojin Cai; Xiang Yu; Weihong Pan; Ming Yao; Jianren Gu; Hong Tu
Journal:  Sci Rep       Date:  2015-01-19       Impact factor: 4.379

10.  Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.

Authors:  Rami Alzhrani; Hashem O Alsaab; Kushal Vanamal; Ketki Bhise; Katyayani Tatiparti; Ayatakshi Barari; Samaresh Sau; Arun K Iyer
Journal:  Adv Ther (Weinh)       Date:  2021-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.